WuXi Vaccines, a global vaccine CDMO reported the successful GMP release of its CHO cell-based drug substance (DS) manufacturing facility located in Suzhou, China. DS production has already begun at the facility. The GMP release of its first DS facility in China enhances WuXi Vaccines’ capability in providing global partners with comprehensive services and in meeting increased demand for vaccine development and manufacture. The DS facility employs the CHO cell-culture platform and utili...